Welcome!

News Feed Item

Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2014

LONDON, April 28, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2014

http://www.reportbuyer.com/pharma_healthcare/research_rd/clinical_trials/non_small_cell_lung_cancer_global_clinical_trials_review.html

Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2014

Summary

GlobalData's clinical trial report, "Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2014" provides data on the Non-Small Cell Lung Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Non-Small Cell Lung Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Non-Small Cell Lung Cancer. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Introduction 6
Non-Small Cell Lung Cancer 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Non-Small Cell Lung Cancer to Oncology Clinical Trials 15

Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Non-Small Cell Lung Cancer to Oncology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Non-Small Cell Lung Cancer 25
Subjects Recruited Over a Period of Time 57
Clinical Trials by Sponsor Type 58
Prominent Sponsors 59
Top Companies Participating in Non-Small Cell Lung Cancer Therapeutics Clinical Trials 60
Prominent Drugs 62

Latest Clinical Trials News on Non-Small Cell Lung Cancer 63
Mar 02, 2014: Genentech Provides Update on Phase III Study of Onartuzumab in People with Specific Type of Lung Cancer 63
Feb 19, 2014: Lilly Announces Ramucirumab Phase III Lung Cancer Trial Meets Primary Endpoint of Overall Survival 63
Feb 17, 2014: Afatinib: added benefit depends on mutation status 64
Jan 27, 2014: Pfizer Announces Top-Line Results From Two Phase 3 Trials Of Dacomitinib In Patients With Refractory Advanced Non-Small Cell Lung Cancer 65
Jan 16, 2014: ArQule Provides Updates on Clinical Trials in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer with Tivantinib 66
Clinical Trial Profiles 68
Clinical Trial Overview of Top Companies 68
F. Hoffmann-La Roche Ltd. 68
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 68
Eli Lilly and Company 84
Clinical Trial Overview of Eli Lilly and Company 84
AstraZeneca PLC 98
Clinical Trial Overview of AstraZeneca PLC 98
Pfizer Inc. 109
Clinical Trial Overview of Pfizer Inc. 109
Bristol-Myers Squibb Company 117

Clinical Trial Overview of Bristol-Myers Squibb Company 117
Sanofi 123
Clinical Trial Overview of Sanofi 123
Novartis AG 128
Clinical Trial Overview of Novartis AG 128
Merck & Co., Inc. 133
Clinical Trial Overview of Merck & Co., Inc. 133
GlaxoSmithKline plc 137
Clinical Trial Overview of GlaxoSmithKline plc 137
C. H. Boehringer Sohn AG & Co. KG 141
Clinical Trial Overview of C. H. Boehringer Sohn AG & Co. KG 141
Clinical Trial Overview of Top Institutes / Government 145
National Cancer Institute 145
Clinical Trial Overview of National Cancer Institute 145
The University of Texas M. D. Anderson Cancer Center 168
Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center 168
Memorial Sloan Kettering Cancer Center 172
Clinical Trial Overview of Memorial Sloan Kettering Cancer Center 172
West Japan Oncology Group 176
Clinical Trial Overview of West Japan Oncology Group 176
European Organization for Research and Treatment of Cancer 179
Clinical Trial Overview of European Organization for Research and Treatment of Cancer 179
Radiation Therapy Oncology Group 182
Clinical Trial Overview of Radiation Therapy Oncology Group 182
Sun Yat-sen University 184
Clinical Trial Overview of Sun Yat-sen University 184

Eastern Cooperative Oncology Group 186
Clinical Trial Overview of Eastern Cooperative Oncology Group 186
Sarah Cannon Research Institute 188
Clinical Trial Overview of Sarah Cannon Research Institute 188
Barbara Ann Karmanos Cancer Institute 190
Clinical Trial Overview of Barbara Ann Karmanos Cancer Institute 190
Five Key Clinical Profiles 192
Appendix 292
Abbreviations 292
Definitions 292
Research Methodology 293
Secondary Research 293
About GlobalData 294
Contact Us 294
Disclaimer 294
Source 295

List of Tables

Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials by Region, 2014* 7
Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2014* 13
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014* 14
Proportion of Non-Small Cell Lung Cancer to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Non-Small Cell Lung Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Non-Small Cell Lung Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Non-Small Cell Lung Cancer to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Non-Small Cell Lung Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Non-Small Cell Lung Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials by Phase, 2014* 21

Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Non-Small Cell Lung Cancer Therapeutics, Global, Suspended Clinical Trials, 2014* 25
Non-Small Cell Lung Cancer Therapeutics, Global, Withdrawn Clinical Trials, 2014* 28
Non-Small Cell Lung Cancer Therapeutics, Global, Terminated Clinical Trials, 2014* 33
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 57
Non-Small Cell Lung Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 58
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 59
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 61
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 62
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014* 68
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Eli Lilly and Company, 2014* 84
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014* 98

Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 109
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Bristol-Myers Squibb Company, 2014* 117
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2014* 123
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014* 128
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck & Co., Inc., 2014* 133
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014* 137
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by C. H. Boehringer Sohn AG & Co. KG, 2014* 141
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014* 145
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Texas M. D. Anderson Cancer Center, 2014* 168
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Memorial Sloan Kettering Cancer Center, 2014* 172

Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by West Japan Oncology Group, 2014* 176
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by European Organization for Research and Treatment of Cancer, 2014* 179
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Radiation Therapy Oncology Group, 2014* 182
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Sun Yat-sen University, 2014* 184
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Eastern Cooperative Oncology Group, 2014* 186
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Sarah Cannon Research Institute, 2014* 188
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Barbara Ann Karmanos Cancer Institute, 2014* 190

List of Figures
Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2014* 13
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014* 14
Proportion of Non-Small Cell Lung Cancer to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Non-Small Cell Lung Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Non-Small Cell Lung Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17

Proportion of Non-Small Cell Lung Cancer to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Non-Small Cell Lung Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Non-Small Cell Lung Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 57
Non-Small Cell Lung Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 58
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 59
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 60
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 62
GlobalData Methodology 293

Read the full report:
Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2014

http://www.reportbuyer.com/pharma_healthcare/research_rd/clinical_trials/non_small_cell_lung_cancer_global_clinical_trials_review.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
An increasing number of companies are creating products that combine data with analytical capabilities. Running interactive queries on Big Data requires complex architectures to store and query data effectively, typically involving data streams, an choosing efficient file format/database and multiple independent systems that are tied together through custom-engineered pipelines. In his session at @BigDataExpo at @ThingsExpo, Tomer Levi, a senior software engineer at Intel’s Advanced Analytics ...
Internet-of-Things discussions can end up either going down the consumer gadget rabbit hole or focused on the sort of data logging that industrial manufacturers have been doing forever. However, in fact, companies today are already using IoT data both to optimize their operational technology and to improve the experience of customer interactions in novel ways. In his session at @ThingsExpo, Gordon Haff, Red Hat Technology Evangelist, shared examples from a wide range of industries – including en...
In IT, we sometimes coin terms for things before we know exactly what they are and how they’ll be used. The resulting terms may capture a common set of aspirations and goals – as “cloud” did broadly for on-demand, self-service, and flexible computing. But such a term can also lump together diverse and even competing practices, technologies, and priorities to the point where important distinctions are glossed over and lost.
Detecting internal user threats in the Big Data eco-system is challenging and cumbersome. Many organizations monitor internal usage of the Big Data eco-system using a set of alerts. This is not a scalable process given the increase in the number of alerts with the accelerating growth in data volume and user base. Organizations are increasingly leveraging machine learning to monitor only those data elements that are sensitive and critical, autonomously establish monitoring policies, and to detect...
"We're a cybersecurity firm that specializes in engineering security solutions both at the software and hardware level. Security cannot be an after-the-fact afterthought, which is what it's become," stated Richard Blech, Chief Executive Officer at Secure Channels, in this SYS-CON.tv interview at @ThingsExpo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Most companies are adopting or evaluating container technology - Docker in particular - to speed up application deployment, drive down cost, ease management and make application delivery more flexible overall. As with most new architectures, this dream takes a lot of work to become a reality. Even when you do get your application componentized enough and packaged properly, there are still challenges for DevOps teams to making the shift to continuous delivery and achieving that reduction in cost ...
Enterprise architects are increasingly adopting multi-cloud strategies as they seek to utilize existing data center assets, leverage the advantages of cloud computing and avoid cloud vendor lock-in. This requires a globally aware traffic management strategy that can monitor infrastructure health across data centers and end-user experience globally, while responding to control changes and system specification at the speed of today’s DevOps teams. In his session at 20th Cloud Expo, Josh Gray, Chie...
To get the most out of their data, successful companies are not focusing on queries and data lakes, they are actively integrating analytics into their operations with a data-first application development approach. Real-time adjustments to improve revenues, reduce costs, or mitigate risk rely on applications that minimize latency on a variety of data sources. Jack Norris reviews best practices to show how companies develop, deploy, and dynamically update these applications and how this data-first...
Intelligent Automation is now one of the key business imperatives for CIOs and CISOs impacting all areas of business today. In his session at 21st Cloud Expo, Brian Boeggeman, VP Alliances & Partnerships at Ayehu, will talk about how business value is created and delivered through intelligent automation to today’s enterprises. The open ecosystem platform approach toward Intelligent Automation that Ayehu delivers to the market is core to enabling the creation of the self-driving enterprise.
"At the keynote this morning we spoke about the value proposition of Nutanix, of having a DevOps culture and a mindset, and the business outcomes of achieving agility and scale, which everybody here is trying to accomplish," noted Mark Lavi, DevOps Solution Architect at Nutanix, in this SYS-CON.tv interview at @DevOpsSummit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"We're here to tell the world about our cloud-scale infrastructure that we have at Juniper combined with the world-class security that we put into the cloud," explained Lisa Guess, VP of Systems Engineering at Juniper Networks, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
Historically, some banking activities such as trading have been relying heavily on analytics and cutting edge algorithmic tools. The coming of age of powerful data analytics solutions combined with the development of intelligent algorithms have created new opportunities for financial institutions. In his session at 20th Cloud Expo, Sebastien Meunier, Head of Digital for North America at Chappuis Halder & Co., discussed how these tools can be leveraged to develop a lasting competitive advantage ...
As businesses adopt functionalities in cloud computing, it’s imperative that IT operations consistently ensure cloud systems work correctly – all of the time, and to their best capabilities. In his session at @BigDataExpo, Bernd Harzog, CEO and founder of OpsDataStore, presented an industry answer to the common question, “Are you running IT operations as efficiently and as cost effectively as you need to?” He then expounded on the industry issues he frequently came up against as an analyst, and ...
The question before companies today is not whether to become intelligent, it’s a question of how and how fast. The key is to adopt and deploy an intelligent application strategy while simultaneously preparing to scale that intelligence. In her session at 21st Cloud Expo, Sangeeta Chakraborty, Chief Customer Officer at Ayasdi, will provide a tactical framework to become a truly intelligent enterprise, including how to identify the right applications for AI, how to build a Center of Excellence to ...
In his session at 20th Cloud Expo, Mike Johnston, an infrastructure engineer at Supergiant.io, discussed how to use Kubernetes to set up a SaaS infrastructure for your business. Mike Johnston is an infrastructure engineer at Supergiant.io with over 12 years of experience designing, deploying, and maintaining server and workstation infrastructure at all scales. He has experience with brick and mortar data centers as well as cloud providers like Digital Ocean, Amazon Web Services, and Rackspace. H...